Spyre Therapeutics
SYRE
129 hedge funds and large institutions have $953M invested in Spyre Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 17 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 25
74% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $603K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2.49% more ownership
Funds ownership: 103.07% → 105.56% (+2.5%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 129 → 129 (0)
5% less capital invested
Capital invested by funds: $1B → $953M (-$51.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$17M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.1M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$9.27M |
| 4 |
BlackRock
New York
|
+$6.43M |
| 5 |
Morgan Stanley
New York
|
+$4.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$15.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$11.6M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.35M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.86M |
SYRE Hedge Fund Activity: Q2 2025 in Review
129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2025, worth a combined $953M — down 5.1% from $1B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SYRE positions and 17 closed out — a net gain of 1 holder — while 64 added to existing stakes and 25 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $17M. The largest seller was Janus Henderson Group, cutting an estimated $15.2M.
- 129 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $953M of Spyre Therapeutics stock for Q2 2025, down 5.1% quarter-over-quarter.
- 18 funds opened new Spyre Therapeutics positions in Q2 2025 and 17 closed out, a net change of +1 holder.
- The largest Spyre Therapeutics buyer in Q2 2025 was Tang Capital Management, an estimated $17M added.
- The largest Spyre Therapeutics seller in Q2 2025 was Janus Henderson Group, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2025.